NCT05208047Phase 3Recruiting

(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal Tumors

Study sponsor: Cogent Biosciences, Inc. · COGT

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-09-30Actual
Enrollment · participants482Estimated
Source updated2026-11-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Active not recruiting. After: Recruiting.

Check registry source

· 1 field changed

Planned enrollment increased by 40 participants

Before: 442 participants (planned). After: 482 participants (planned).

Check registry source

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Jul 2025. After: 30 Sep 2025.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview